Indraprastha Medical Corporation Ltd: Share Price Analysis, Intrinsic Value & Fundamentals (2025)

Share Price and Basic Stock Data

Last Updated: March 8, 2025, 1:45 pm

Market Cap	3,116 Cr.
Current Price	340
High / Low	572/154
Stock P/E	20.6
Book Value	57.2
Dividend Yield	1.32 %
ROCE	38.4 %
ROE	29.1 %
Face Value	10.0
PEG Ratio	0.16

Stock P/E, Current Price, and Intrinsic Value Over Time

Stock P/E Current Price Intrinsic Value

View Share Price Target for Indraprastha Medical Corporation Ltd

Competitors of Indraprastha Medical Corporation Ltd

Stock Name ⇩	Market Cap ⇩	Current Price ⇩	High / Low ⇩	Stock P/E ⇩	Book Value ⇩	Dividend Yield ⇩	ROCE ⇩	ROE ⇩	Face Value ⇩
NG Industries Ltd	57.0 Cr.	170	206/136	4.70	124	2.06 %	6.50 %	5.63 %	10.0
Global Longlife Hospital and Research Ltd	25.5 Cr.	24.2	46.4/22.1		25.9	0.00 %	2.51 %	4.72 %	10.0
Gian Lifecare Ltd	18.1 Cr.	17.5	29.0/12.1	4.43	19.2	0.00 %	29.2 %	24.6 %	10.0
Fortis Malar Hospitals Ltd	118 Cr.	62.7	108/44.0	153	15.9	67.8 %	3.29 %	9.12 %	10.0
Family Care Hospitals Ltd	26.7 Cr.	4.95	9.50/4.32	0.70	2.67	0.00 %	15.4 %	24.1 %	10.0
Industry Average	22,314.27 Cr	670.23		53.44	89.39	3.10%	12.34%	12.42%	9.12

All Competitor Stocks of Indraprastha Medical Corporation Ltd

Quarterly Result

Metric	Dec 2021	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Sales	237	216	263	284	277	274	307	317	306	315	348	350	325
Expenses	205	188	226	241	240	241	259	267	259	266	281	286	273
Operating Profit	31	28	37	44	37	33	47	50	47	48	67	64	52
OPM %	13%	13%	14%	15%	13%	12%	15%	16%	15%	15%	19%	18%	16%
Other Income	1	2	1	1	3	5	4	4	4	5	5	6	5
Interest	1	1	1	1	1	1	1	1	1	2	2	2	2
Depreciation	9	9	10	10	10	10	10	10	10	10	11	11	11
Profit before tax	22	20	27	34	29	27	40	44	41	42	60	57	45
Tax %	28%	24%	24%	26%	29%	27%	24%	25%	28%	25%	25%	26%	26%
Net Profit	16	15	20	25	21	20	30	33	29	31	45	42	33
EPS in Rs	1.74	1.66	2.21	2.74	2.28	2.16	3.33	3.58	3.21	3.40	4.88	4.63	3.58

Last Updated: February 28, 2025, 7:16 pm

Below is a detailed analysis of the quarterly data for Indraprastha Medical Corporation Ltd based on the most recent figures (Dec 2024) and their trends compared to the previous period:

For Sales, as of Dec 2024, the value is ₹325.00 Cr.. The value appears to be declining and may need further review. It has decreased from 350.00 Cr. (Sep 2024) to ₹325.00 Cr., marking a decrease of 25.00 Cr..
For Expenses, as of Dec 2024, the value is ₹273.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 286.00 Cr. (Sep 2024) to ₹273.00 Cr., marking a decrease of 13.00 Cr..
For Operating Profit, as of Dec 2024, the value is ₹52.00 Cr.. The value appears to be declining and may need further review. It has decreased from 64.00 Cr. (Sep 2024) to ₹52.00 Cr., marking a decrease of 12.00 Cr..
For OPM %, as of Dec 2024, the value is 16.00%. The value appears to be declining and may need further review. It has decreased from 18.00% (Sep 2024) to 16.00%, marking a decrease of 2.00%.
For Other Income, as of Dec 2024, the value is ₹5.00 Cr.. The value appears to be declining and may need further review. It has decreased from 6.00 Cr. (Sep 2024) to ₹5.00 Cr., marking a decrease of 1.00 Cr..
For Interest, as of Dec 2024, the value is ₹2.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 2.00 Cr..
For Depreciation, as of Dec 2024, the value is ₹11.00 Cr.. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 11.00 Cr..
For Profit before tax, as of Dec 2024, the value is ₹45.00 Cr.. The value appears to be declining and may need further review. It has decreased from 57.00 Cr. (Sep 2024) to ₹45.00 Cr., marking a decrease of 12.00 Cr..
For Tax %, as of Dec 2024, the value is 26.00%. The value remains steady. There is no change compared to the previous period (Sep 2024) which recorded 26.00%.
For Net Profit, as of Dec 2024, the value is ₹33.00 Cr.. The value appears to be declining and may need further review. It has decreased from 42.00 Cr. (Sep 2024) to ₹33.00 Cr., marking a decrease of 9.00 Cr..
For EPS in Rs, as of Dec 2024, the value is 3.58. The value appears to be declining and may need further review. It has decreased from ₹4.63 (Sep 2024) to 3.58, marking a decrease of ₹1.05.

Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: March 6, 2025, 3:56 pm

Metric	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	TTM
Sales	607	678	714	755	766	753	788	831	613	888	1,099	1,245	1,337
Expenses	528	587	630	675	686	678	706	743	572	768	947	1,050	1,106
Operating Profit	79	91	85	80	79	74	82	87	41	120	152	195	231
OPM %	13%	13%	12%	11%	10%	10%	10%	11%	7%	14%	14%	16%	17%
Other Income	1	1	1	1	-0	-1	-1	-0	-0	-3	9	16	21
Interest	9	10	8	7	8	9	7	6	3	3	4	4	6
Depreciation	26	28	28	35	31	31	30	33	33	35	39	40	44
Profit before tax	45	54	50	39	41	34	45	48	4	79	117	166	203
Tax %	37%	35%	34%	37%	36%	38%	36%	9%	46%	26%	26%	25%
Net Profit	29	35	32	24	26	21	28	44	2	59	86	124	151
EPS in Rs	3.14	3.87	3.54	2.66	2.86	2.30	3.10	4.76	0.25	6.39	9.40	13.52	16.49
Dividend Payout %	51%	47%	51%	68%	63%	65%	52%	0%	0%	39%	32%	33%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year	2013-2014	2014-2015	2015-2016	2016-2017	2017-2018	2018-2019	2019-2020	2020-2021	2021-2022	2022-2023	2023-2024
YoY Net Profit Growth (%)	20.69%	-8.57%	-25.00%	8.33%	-19.23%	33.33%	57.14%	-95.45%	2850.00%	45.76%	44.19%
Change in YoY Net Profit Growth (%)	0.00%	-29.26%	-16.43%	33.33%	-27.56%	52.56%	23.81%	-152.60%	2945.45%	-2804.24%	-1.58%

Indraprastha Medical Corporation Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2013-2014 to 2023-2024.

Growth

Compounded Sales Growth
10 Years:	6%
5 Years:	10%
3 Years:	27%
TTM:	11%

Compounded Profit Growth
10 Years:	13%
5 Years:	34%
3 Years:	258%
TTM:	34%

Stock Price CAGR
10 Years:	19%
5 Years:	57%
3 Years:	71%
1 Year:	89%

Return on Equity
10 Years:	17%
5 Years:	20%
3 Years:	25%
Last Year:	29%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 11:30 pm

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024	Sep 2024
Equity Capital	92	92	92	92	92	92	92	92	92	92	92	92	92
Reserves	79	95	103	132	139	141	152	176	181	234	288	386	433
Borrowings	73	63	50	52	67	66	21	4	3	5	2	34	33
Other Liabilities	194	199	196	185	160	134	157	177	157	131	173	212	249
Total Liabilities	438	449	442	460	458	432	422	449	432	462	555	723	806
Fixed Assets	300	293	286	301	296	294	280	303	283	277	275	347	341
CWIP	0	2	3	3	0	0	1	0	3	0	3	0	0
Investments	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets	138	154	153	157	163	138	141	146	145	185	278	376	465
Total Assets	438	449	442	460	458	432	422	449	432	462	555	723	806

Below is a detailed analysis of the balance sheet data for Indraprastha Medical Corporation Ltd based on the most recent figures (Sep 2024) and their trends compared to the previous period:

For Equity Capital, as of Sep 2024, the value is ₹92.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹92.00 Cr..
For Reserves, as of Sep 2024, the value is ₹433.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹386.00 Cr. (Mar 2024) to ₹433.00 Cr., marking an increase of 47.00 Cr..
For Borrowings, as of Sep 2024, the value is ₹33.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from ₹34.00 Cr. (Mar 2024) to ₹33.00 Cr., marking a decrease of 1.00 Cr..
For Other Liabilities, as of Sep 2024, the value is ₹249.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹212.00 Cr. (Mar 2024) to ₹249.00 Cr., marking an increase of 37.00 Cr..
For Total Liabilities, as of Sep 2024, the value is ₹806.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from ₹723.00 Cr. (Mar 2024) to ₹806.00 Cr., marking an increase of 83.00 Cr..
For Fixed Assets, as of Sep 2024, the value is ₹341.00 Cr.. The value appears to be declining and may need further review. It has decreased from ₹347.00 Cr. (Mar 2024) to ₹341.00 Cr., marking a decrease of 6.00 Cr..
For CWIP, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Investments, as of Sep 2024, the value is ₹0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded ₹0.00 Cr..
For Other Assets, as of Sep 2024, the value is ₹465.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹376.00 Cr. (Mar 2024) to ₹465.00 Cr., marking an increase of 89.00 Cr..
For Total Assets, as of Sep 2024, the value is ₹806.00 Cr.. The value appears strong and on an upward trend. It has increased from ₹723.00 Cr. (Mar 2024) to ₹806.00 Cr., marking an increase of 83.00 Cr..

Notably, the Reserves (₹433.00 Cr.) exceed the Borrowings (33.00 Cr.), indicating a solid financial buffer.

Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.

Reserves and Borrowings Chart

Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Cash from Operating Activity +	67	58	64	62	28	48	75	86	27	94	144	200
Cash from Investing Activity +	-54	-22	-29	-33	-22	-30	-17	-40	-19	-74	-108	-158
Cash from Financing Activity +	-13	-36	-35	-30	-5	-17	-44	-43	-3	-3	-26	-32
Net Cash Flow	0	0	-0	-0	-0	1	14	4	5	17	11	9

Free Cash Flow

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Free Cash Flow	6.00	28.00	35.00	28.00	12.00	8.00	61.00	83.00	38.00	115.00	150.00	161.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

Month	Mar 2013	Mar 2014	Mar 2015	Mar 2016	Mar 2017	Mar 2018	Mar 2019	Mar 2020	Mar 2021	Mar 2022	Mar 2023	Mar 2024
Debtor Days	32	35	40	41	47	41	35	35	40	18	23	17
Inventory Days
Days Payable
Cash Conversion Cycle	32	35	40	41	47	41	35	35	40	18	23	17
Working Capital Days	-28	-19	-23	0	14	12	-5	-8	0	-1	-11	-24
ROCE %	23%	26%	23%	18%	17%	15%	19%	21%	3%	29%	34%	38%

Financial Efficiency Indicators Chart

Share Holding Pattern

Month	Mar 2022	Jun 2022	Sep 2022	Dec 2022	Mar 2023	Jun 2023	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024
Promoters	51.00%	51.00%	51.00%	51.00%	51.00%	51.00%	51.00%	51.00%	51.00%	51.00%	51.00%	51.00%
FIIs	0.14%	0.09%	0.15%	0.77%	0.27%	0.37%	0.81%	0.95%	1.08%	1.70%	2.64%	2.88%
DIIs	0.02%	0.02%	0.02%	0.00%	0.00%	0.00%	6.71%	6.36%	4.91%	3.14%	3.19%	3.18%
Public	48.84%	48.89%	48.83%	48.22%	48.72%	48.62%	41.49%	41.69%	43.01%	44.14%	43.16%	42.91%
No. of Shareholders	56,540	55,290	55,287	52,760	49,833	48,630	47,865	51,448	54,158	55,103	64,671	69,697

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund Name	No of Shares	AUM (%)	Amount Invested (Cr)	Previous Number of Shares	Previous Date	Percentage Change
Motilal Oswal S&P BSE Healthcare ETF	384	0.08	0.01	384	2025-03-06	0%

ROCE Trend

EPS Trend

Key Financial Ratios

Month	Mar 24	Mar 23	Mar 22	Mar 21	Mar 20
FaceValue	10.00	10.00	10.00	10.00	10.00
Basic EPS (Rs.)	13.52	9.40	6.39	0.25	4.76
Diluted EPS (Rs.)	13.52	9.40	6.39	0.25	4.76
Cash EPS (Rs.)	17.89	13.68	10.21	3.89	8.36
Book Value[Excl.RevalReserv]/Share (Rs.)	52.12	41.39	35.50	29.75	29.21
Book Value[Incl.RevalReserv]/Share (Rs.)	52.12	41.39	35.50	29.75	29.21
Dividend / Share (Rs.)	4.50	3.00	2.50	0.00	0.00
Revenue From Operations / Share (Rs.)	135.78	119.85	96.89	66.91	90.62
PBDIT / Share (Rs.)	22.93	17.53	12.81	4.47	9.50
PBIT / Share (Rs.)	18.56	13.25	9.00	0.83	5.90
PBT / Share (Rs.)	18.12	12.78	8.63	0.46	5.26
Net Profit / Share (Rs.)	13.52	9.40	6.39	0.25	4.76
PBDIT Margin (%)	16.89	14.62	13.22	6.67	10.48
PBIT Margin (%)	13.67	11.05	9.28	1.24	6.51
PBT Margin (%)	13.34	10.66	8.90	0.69	5.80
Net Profit Margin (%)	9.95	7.84	6.60	0.37	5.25
Return on Networth / Equity (%)	25.94	22.70	18.01	0.85	16.28
Return on Capital Employeed (%)	30.50	28.54	22.40	2.41	17.48
Return On Assets (%)	17.13	15.51	12.69	0.53	9.71
Total Debt / Equity (X)	0.00	0.00	0.00	0.00	0.01
Asset Turnover Ratio (%)	1.95	2.16	1.99	1.39	1.91
Current Ratio (X)	1.86	1.72	1.68	1.22	1.01
Quick Ratio (X)	1.82	1.66	1.58	1.14	0.92
Inventory Turnover Ratio (X)	0.00	21.00	18.55	10.95	14.88
Dividend Payout Ratio (NP) (%)	22.18	26.60	0.00	0.00	0.00
Dividend Payout Ratio (CP) (%)	16.76	18.27	0.00	0.00	0.00
Earning Retention Ratio (%)	77.82	73.40	0.00	0.00	0.00
Cash Earning Retention Ratio (%)	83.24	81.73	0.00	0.00	0.00
Interest Coverage Ratio (X)	51.79	37.55	34.43	12.27	14.72
Interest Coverage Ratio (Post Tax) (X)	31.53	21.13	18.19	1.70	8.37
Enterprise Value (Cr.)	1350.00	583.80	467.36	465.22	291.19
EV / Net Operating Revenue (X)	1.08	0.53	0.52	0.75	0.35
EV / EBITDA (X)	6.42	3.63	3.98	11.36	3.34
MarketCap / Net Operating Revenue (X)	1.26	0.64	0.60	0.80	0.37
Retention Ratios (%)	77.81	73.39	0.00	0.00	0.00
Price / BV (X)	3.30	1.88	1.65	1.81	1.16
Price / Net Operating Revenue (X)	1.26	0.64	0.60	0.80	0.37
EarningsYield	0.07	0.12	0.10	0.00	0.14

After reviewing the key financial ratios for Indraprastha Medical Corporation Ltd, here is a detailed analysis based on the latest available data and recent trends:

For FaceValue, as of Mar 24, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 10.00.
For Basic EPS (Rs.), as of Mar 24, the value is 13.52. This value is within the healthy range. It has increased from 9.40 (Mar 23) to 13.52, marking an increase of 4.12.
For Diluted EPS (Rs.), as of Mar 24, the value is 13.52. This value is within the healthy range. It has increased from 9.40 (Mar 23) to 13.52, marking an increase of 4.12.
For Cash EPS (Rs.), as of Mar 24, the value is 17.89. This value is within the healthy range. It has increased from 13.68 (Mar 23) to 17.89, marking an increase of 4.21.
For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 52.12. It has increased from 41.39 (Mar 23) to 52.12, marking an increase of 10.73.
For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 24, the value is 52.12. It has increased from 41.39 (Mar 23) to 52.12, marking an increase of 10.73.
For Dividend / Share (Rs.), as of Mar 24, the value is 4.50. This value exceeds the healthy maximum of 3. It has increased from 3.00 (Mar 23) to 4.50, marking an increase of 1.50.
For Revenue From Operations / Share (Rs.), as of Mar 24, the value is 135.78. It has increased from 119.85 (Mar 23) to 135.78, marking an increase of 15.93.
For PBDIT / Share (Rs.), as of Mar 24, the value is 22.93. This value is within the healthy range. It has increased from 17.53 (Mar 23) to 22.93, marking an increase of 5.40.
For PBIT / Share (Rs.), as of Mar 24, the value is 18.56. This value is within the healthy range. It has increased from 13.25 (Mar 23) to 18.56, marking an increase of 5.31.
For PBT / Share (Rs.), as of Mar 24, the value is 18.12. This value is within the healthy range. It has increased from 12.78 (Mar 23) to 18.12, marking an increase of 5.34.
For Net Profit / Share (Rs.), as of Mar 24, the value is 13.52. This value is within the healthy range. It has increased from 9.40 (Mar 23) to 13.52, marking an increase of 4.12.
For PBDIT Margin (%), as of Mar 24, the value is 16.89. This value is within the healthy range. It has increased from 14.62 (Mar 23) to 16.89, marking an increase of 2.27.
For PBIT Margin (%), as of Mar 24, the value is 13.67. This value is within the healthy range. It has increased from 11.05 (Mar 23) to 13.67, marking an increase of 2.62.
For PBT Margin (%), as of Mar 24, the value is 13.34. This value is within the healthy range. It has increased from 10.66 (Mar 23) to 13.34, marking an increase of 2.68.
For Net Profit Margin (%), as of Mar 24, the value is 9.95. This value is within the healthy range. It has increased from 7.84 (Mar 23) to 9.95, marking an increase of 2.11.
For Return on Networth / Equity (%), as of Mar 24, the value is 25.94. This value is within the healthy range. It has increased from 22.70 (Mar 23) to 25.94, marking an increase of 3.24.
For Return on Capital Employeed (%), as of Mar 24, the value is 30.50. This value is within the healthy range. It has increased from 28.54 (Mar 23) to 30.50, marking an increase of 1.96.
For Return On Assets (%), as of Mar 24, the value is 17.13. This value is within the healthy range. It has increased from 15.51 (Mar 23) to 17.13, marking an increase of 1.62.
For Total Debt / Equity (X), as of Mar 24, the value is 0.00. This value is within the healthy range. There is no change compared to the previous period (Mar 23) which recorded 0.00.
For Asset Turnover Ratio (%), as of Mar 24, the value is 1.95. It has decreased from 2.16 (Mar 23) to 1.95, marking a decrease of 0.21.
For Current Ratio (X), as of Mar 24, the value is 1.86. This value is within the healthy range. It has increased from 1.72 (Mar 23) to 1.86, marking an increase of 0.14.
For Quick Ratio (X), as of Mar 24, the value is 1.82. This value is within the healthy range. It has increased from 1.66 (Mar 23) to 1.82, marking an increase of 0.16.
For Inventory Turnover Ratio (X), as of Mar 24, the value is 0.00. This value is below the healthy minimum of 4. It has decreased from 21.00 (Mar 23) to 0.00, marking a decrease of 21.00.
For Dividend Payout Ratio (NP) (%), as of Mar 24, the value is 22.18. This value is within the healthy range. It has decreased from 26.60 (Mar 23) to 22.18, marking a decrease of 4.42.
For Dividend Payout Ratio (CP) (%), as of Mar 24, the value is 16.76. This value is below the healthy minimum of 20. It has decreased from 18.27 (Mar 23) to 16.76, marking a decrease of 1.51.
For Earning Retention Ratio (%), as of Mar 24, the value is 77.82. This value exceeds the healthy maximum of 70. It has increased from 73.40 (Mar 23) to 77.82, marking an increase of 4.42.
For Cash Earning Retention Ratio (%), as of Mar 24, the value is 83.24. This value exceeds the healthy maximum of 70. It has increased from 81.73 (Mar 23) to 83.24, marking an increase of 1.51.
For Interest Coverage Ratio (X), as of Mar 24, the value is 51.79. This value is within the healthy range. It has increased from 37.55 (Mar 23) to 51.79, marking an increase of 14.24.
For Interest Coverage Ratio (Post Tax) (X), as of Mar 24, the value is 31.53. This value is within the healthy range. It has increased from 21.13 (Mar 23) to 31.53, marking an increase of 10.40.
For Enterprise Value (Cr.), as of Mar 24, the value is 1,350.00. It has increased from 583.80 (Mar 23) to 1,350.00, marking an increase of 766.20.
For EV / Net Operating Revenue (X), as of Mar 24, the value is 1.08. This value is within the healthy range. It has increased from 0.53 (Mar 23) to 1.08, marking an increase of 0.55.
For EV / EBITDA (X), as of Mar 24, the value is 6.42. This value is within the healthy range. It has increased from 3.63 (Mar 23) to 6.42, marking an increase of 2.79.
For MarketCap / Net Operating Revenue (X), as of Mar 24, the value is 1.26. This value is within the healthy range. It has increased from 0.64 (Mar 23) to 1.26, marking an increase of 0.62.
For Retention Ratios (%), as of Mar 24, the value is 77.81. This value exceeds the healthy maximum of 70. It has increased from 73.39 (Mar 23) to 77.81, marking an increase of 4.42.
For Price / BV (X), as of Mar 24, the value is 3.30. This value exceeds the healthy maximum of 3. It has increased from 1.88 (Mar 23) to 3.30, marking an increase of 1.42.
For Price / Net Operating Revenue (X), as of Mar 24, the value is 1.26. This value is within the healthy range. It has increased from 0.64 (Mar 23) to 1.26, marking an increase of 0.62.
For EarningsYield, as of Mar 24, the value is 0.07. This value is below the healthy minimum of 5. It has decreased from 0.12 (Mar 23) to 0.07, marking a decrease of 0.05.

Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Indraprastha Medical Corporation Ltd as of March 12, 2025 is: ₹277.93

Calculation basis:

Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of March 12, 2025, Indraprastha Medical Corporation Ltd is Overvalued by 18.26% compared to the current share price 340.00

Intrinsic Value of Indraprastha Medical Corporation Ltd as of March 12, 2025 is: 642.38

Calculation basis:

Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of March 12, 2025, Indraprastha Medical Corporation Ltd is Undervalued by 88.94% compared to the current share price 340.00

Last 5 Year EPS CAGR: 131.13%

*Investments are subject to market risks

Strength and Weakness

Strength	Weakness
The stock has a high average ROCE of 22.17%, which is a positive sign. The stock has a low average Working Capital Days of -7.75, which is a positive sign. The company has higher reserves (195.31 cr) compared to borrowings (36.38 cr), indicating strong financial stability. The company has shown consistent growth in sales (568.92 cr) and profit (71.15 cr) over the years.	The stock has a high average Cash Conversion Cycle of 33.67, which may not be favorable.

Stock Analysis

Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Indraprastha Medical Corporation Ltd:
1. Net Profit Margin: 9.95%
  - Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
2. ROCE: 30.5% (Industry Average ROCE: 12.34%)
  - ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
3. ROE%: 25.94% (Industry Average ROE: 12.42%)
  - ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
4. Interest Coverage Ratio (Post Tax): 31.53
  - Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
5. Quick Ratio: 1.82
  - Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
6. Stock P/E: 20.6 (Industry average Stock P/E: 53.44)
  - Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
7. Total Debt / Equity: 0
  - Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
Stock Rating:

About the Company - Qualitative Analysis

Indraprastha Medical Corporation Ltd. is a Public Limited Listed company incorporated on 16/03/1988 and has its registered office in the State of Delhi, India. Company's Corporate Identification Number(CIN) is L24232DL1988PLC030958 and registration number is 030958. Currently company belongs to the Industry of Hospitals & Medical Services. Company's Total Operating Revenue is Rs. 1244.70 Cr. and Equity Capital is Rs. 91.67 Cr. for the Year ended 31/03/2024.

INDUSTRY	ADDRESS	CONTACT
Hospitals & Medical Services	Sarita Vihar, Delhi-Mathura Road, New Delhi Delhi 110076	imclshares@apollohospitals.com delhi.apollohospitals.com

Management
Name	Position Held
Dr. Prathap C Reddy	Vice Chairman
Mr. Pattabhiraman Shivakumar	Managing Director
Dr.(Ms.) Suneeta Reddy	Director
Mr. Vinayak Chatterjee	Director
Ms. Vineeta Rai	Director
Ms. Madhumita Ganguli	Director
Dr. Menaka Guruswami	Director
Dr.(Ms.) Sangita Reddy	Director
Dr. Arun Rai	Director
Prof. (Dr) Mahesh Verma	Director
Mr. Salil Singhal	Director
Mr. Sandip Somany	Director
Mr. Tejpreet Singh Chopra	Director

FAQ

What is the latest intrinsic value of Indraprastha Medical Corporation Ltd?

The latest intrinsic value of Indraprastha Medical Corporation Ltd as on 10 March 2025 is ₹277.93, which is 18.26% lower than the current market price of 340.00, indicating the stock is overvalued by 18.26%. The intrinsic value of Indraprastha Medical Corporation Ltd is calculated using PE ratio method. The stock has a market capitalization of ₹3,116 Cr. and recorded a high/low of ₹572/154 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹433 Cr and total liabilities of ₹806 Cr.

What is the Market Cap of Indraprastha Medical Corporation Ltd?

The Market Cap of Indraprastha Medical Corporation Ltd is 3,116 Cr..

What is the current Stock Price of Indraprastha Medical Corporation Ltd as on 10 March 2025?

The current stock price of Indraprastha Medical Corporation Ltd as on 10 March 2025 is ₹340.

What is the High / Low of Indraprastha Medical Corporation Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Indraprastha Medical Corporation Ltd stocks is ₹572/154.

What is the Stock P/E of Indraprastha Medical Corporation Ltd?

The Stock P/E of Indraprastha Medical Corporation Ltd is 20.6.

What is the Book Value of Indraprastha Medical Corporation Ltd?

The Book Value of Indraprastha Medical Corporation Ltd is 57.2.

What is the Dividend Yield of Indraprastha Medical Corporation Ltd?

The Dividend Yield of Indraprastha Medical Corporation Ltd is 1.32 %.

What is the ROCE of Indraprastha Medical Corporation Ltd?

The ROCE of Indraprastha Medical Corporation Ltd is 38.4 %.

What is the ROE of Indraprastha Medical Corporation Ltd?

The ROE of Indraprastha Medical Corporation Ltd is 29.1 %.

What is the Face Value of Indraprastha Medical Corporation Ltd?

The Face Value of Indraprastha Medical Corporation Ltd is 10.0.